Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

María-Victoria Mateos, Silvia Ling, Claudio Cerchione, Peter Rajnics, Massimo Offidani, Fredrik Schjesvold, Masaki Ri, Satoshi Ito, Florence Suzan Teisserenc, Rick Zhang, Maya Stefanova-Urena, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 4044.

https://doi.org/10.1182/blood-2025-4044

Published: 2025

Journal Articles

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Blood (2025) 146 (Supplement 1): 101.

https://doi.org/10.1182/blood-2025-101

Published: 2025

Journal Articles

Personalized prognostic model for multiple myeloma patients using continuous variables

Sonia More', Alfonso Piciocchi, Samuele Confalone, Sara Bringhen, Mattia D'Agostino, Francesca Gay, Michele Cavo, Elena Zamagni, Pieter Sonneveld, Niels W.C.J. Van De Donk, Laura Corvatta, Maria Teresa Petrucci, Francesca Fazio, Mario Boccadoro, Massimo Offidani

Blood (2025) 146 (Supplement 1): 7563.

https://doi.org/10.1182/blood-2025-7563

Published: 2025

Journal Articles

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Blood (2025) 146 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2025-3977

Published: 2025

Journal Articles

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Blood (2025) 146 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2025-4002

Published: 2025

Journal Articles

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro, Velia Bongarzoni, Francesca Fazio, Carmine Liberatore, Giusy Antolino, Silvia Gentili, Angela Rago, Laura De Padua, Paola Arcuri, Barbara Anaclerico, Maria Teresa Petrucci, Elena Rossi, Massimo Offidani, Alessandro Andriani, Roberto Latagliata

Blood (2025) 146 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2025-5777

Published: 2025

Journal Articles

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Blood (2025) 146 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2025-6363

Published: 2025

Journal Articles

Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial

Blood (2025) 146 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2025-6356

Published: 2025

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Sonia More', Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Shahram Kordasti, Attilio Olivieri, Antonella Poloni, Massimo Offidani

Blood (2024) 144 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2024-205518

Published: 2024

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Blood (2023) 142 (Supplement 1): 208.

https://doi.org/10.1182/blood-2023-177564

Published: 2023

Journal Articles

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2023-189193

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Blood (2022) 140 (Supplement 1): 10027–10028.

https://doi.org/10.1182/blood-2022-168619

Published: 2022

Journal Articles

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Erika Morsia, Elena Torre, Francesca Marrara, Sonia Morè, Mauro Petrini, Valentina Maria Manieri, Laura Gurgoglione, Guido Gini, Massimo Offidani, Attilio Olivieri, Serena Rupoli

Blood (2022) 140 (Supplement 1): 11375.

https://doi.org/10.1182/blood-2022-163790

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Personalized prognostic model for multiple myeloma patients using continuous variables

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only